Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4099 - Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Dpt experience.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Dario Loparco

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

D. Loparco, L. Orlando, M. Caloro, P. Fedele, P. Schiavone, A. Quaranta, C. Caliolo, M. Cinefra, P. Ferrara, L.L. Falcone, V. Capone, C. Destro, A. Morleo, A. Ricco, V. Bonuso, G. Lotti, M. D'amico, P. Rizzo, A. Marino, S. Cinieri

Author affiliations

  • Uoc Oncologia Medica, Ospedale A. Perrino, 72100 - Brindisi/IT
More

Resources

Abstract 4099

Background

The cancer treatments (T) bring with it body image challenges, causing low self-esteem and contributing to worsen the quality of life. Chemotherapy (CT)-induced hair loss (HL) is one of the most emotionally distressing side effects of several breast cancer (BC) T. The DigniCap system (DCS), using the scalp cooling system, has been shown to reduce CT-induced alopecia (A) in a multicenter prospective trial. The purpose of this prospective observational study was to describe our experience.

Methods

Two DCS device are available at the Brindisi Oncology Dpt. From February 2016 and May 2018, 86 consecutive early stage BC pts who received anthracycline and/or taxane-based T were enrolled. A nurse and a psychologist were dedicated for these pts. Success of scalp cooling was defined according to the Dean’s scale: G0= no HL; G1 < 25% HL; G2=25–50% HL; G3=50–75% HL; G4 >75% HL.

Results

A total of 86 women were included in the following T cohorts: n = 37 (43%) received 4 courses of EC (IV) on day 1, with 21 days between cycles) followed by 12 courses of weekly Paclitaxel (P); n = 39 (45%) received only 4 courses of EC and n = 10 pts (12%) P and concurrent weeklyTrastuzumab for 12 consecutive doses. Median age was 48 years (range 31-74). Overall success (G0-G2) was observed in 61 pts (71%). Full preservation of the hair (G0) was observed in 16 pts (19%), G1 in 31 pts (36%) and G2 in 14 pts (16%) (tab 1). Most frequent scalp cooling-related symptoms were: coldness (n = 70, 81%) and headache (n = 60, 70%). Overall, 11% (n = 9) of pts discontinued DCS because of unsatisfactory hair preservation (n = 5, 6%) and cold discomfort (n = 2; 2.5%). Furthermore, we observed a hair growth when DCS was continued for pts with A G3 – G4.Table: 1795P

ALOPECIA H/LG0G1G2G3G4
N (%)16 (19%)31(36%)14(16%)20 (23%)5 (6%)

Tab 1: A/HL

Conclusions

Our results reinforced previous evidences, showing that DCS is a good chance to prevent A during CT with anthracycline and/or taxane-based regimen and supported the wider use to all women with early stage BC.

Clinical trial identification

Legal entity responsible for the study

Saverio Cinieri.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.